Skip Therapeutics is developing RNA therapeutics for treatment of rare genetic diseases.
![](http://rmgpfund.com/wp-content/uploads/2021/11/Frame-27-300x150.png)
Scientific approach
A proprietary computational engine is used to identify disease-causing mutations. Antisense oligonucleotides (ASO) are then developed to modulate splicing in order to generate functional proteins. This approach allows identification of relevant patient cohorts and design of ASOs.
Indications
Rare genetic diseases
Team
Prof. Erez Levanon, PhD – Inventor
Prof. Rotem Karni, PhD – Inventor
Ariel Feiglin, PhD – CSO